Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor
出版年份 2015 全文链接
标题
Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor
作者
关键词
Hepatotoxicity, TAS266, Nanobody<sup>®</sup>, DR5 receptor, Immunogenicity
出版物
CANCER CHEMOTHERAPY AND PHARMACOLOGY
Volume 75, Issue 5, Pages 887-895
出版商
Springer Nature
发表日期
2015-02-26
DOI
10.1007/s00280-015-2712-0
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- OP0043 Twenty-Four Weeks of Treatment with a Novel Anti-IL-6 Receptor Nanobody® (ALX-0061) Resulted in 84% ACR20 Improvement and 58% DAS28 Remission in a Phase I/Ii Study in RA
- (2014) J.-B. Holz et al. ANNALS OF THE RHEUMATIC DISEASES
- Multivalent nanobodies targeting death receptor 5 elicit superior tumor cell killing through efficient caspase induction
- (2014) Heather A Huet et al. mAbs
- Evaluation of Pre-existing Antibody Presence as a Risk Factor for Posttreatment Anti-drug Antibody Induction: Analysis of Human Clinical Study Data for Multiple Biotherapeutics
- (2013) Li Xue et al. AAPS Journal
- Pre-Existing Biotherapeutic-Reactive Antibodies: Survey Results Within the American Association of Pharmaceutical Scientists
- (2013) Li Xue et al. AAPS Journal
- The TRAIL of oncogenes to apoptosis
- (2013) Eftychia Oikonomou et al. BIOFACTORS
- Safety, pharmacokinetics, and pharmacodynamics of the DR5 antibody LBY135 alone and in combination with capecitabine in patients with advanced solid tumors
- (2013) Sunil Sharma et al. INVESTIGATIONAL NEW DRUGS
- Autoantibodies to Variable Heavy (VH) Chain Ig Sequences in Humans Impact the Safety and Clinical Pharmacology of a VH Domain Antibody Antagonist of TNF-α Receptor 1
- (2013) M. C. Holland et al. JOURNAL OF CLINICAL IMMUNOLOGY
- A Randomized Phase 2 Study of Paclitaxel and Carboplatin with or without Conatumumab for First-Line Treatment of Advanced Non–Small-Cell Lung Cancer
- (2013) Luis Paz-Ares et al. Journal of Thoracic Oncology
- Novel Antiplatelet Agents: ALX-0081, a Nanobody Directed towards von Willebrand Factor
- (2013) Jozef Bartunek et al. Journal of Cardiovascular Translational Research
- Phase Ib Study of Drozitumab Combined With First-Line mFOLFOX6 Plus Bevacizumab in Patients with Metastatic Colorectal Cancer
- (2012) Caio M. Rocha Lima et al. CANCER INVESTIGATION
- First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: A Phase I/II open-label and double-blind study
- (2012) George D. Demetri et al. EUROPEAN JOURNAL OF CANCER
- The developing clinical problem of chemotherapy-induced hepatic injury
- (2011) Charles H. C. Pilgrim et al. ANZ JOURNAL OF SURGERY
- Randomized Phase II Study of Dulanermin in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Advanced Non–Small-Cell Lung Cancer
- (2011) Jean-Charles Soria et al. JOURNAL OF CLINICAL ONCOLOGY
- Chemotherapy-induced Liver Injury in Metastatic Colorectal Cancer: Semiquantitative Histologic Analysis of 334 Resected Liver Specimens Shows That Vascular Injury but not Steatohepatitis Is Associated With Preoperative Chemotherapy
- (2010) Paul Ryan et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Phase I Trial of Weekly Tigatuzumab, an Agonistic Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5)
- (2010) Andres Forero-Torres et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- A Phase I Safety and Pharmacokinetic Study of the Death Receptor 5 Agonistic Antibody PRO95780 in Patients with Advanced Malignancies
- (2010) D. R. Camidge et al. CLINICAL CANCER RESEARCH
- Phase I Dose-Escalation Study of Recombinant Human Apo2L/TRAIL, a Dual Proapoptotic Receptor Agonist, in Patients With Advanced Cancer
- (2010) Roy S. Herbst et al. JOURNAL OF CLINICAL ONCOLOGY
- New insights into apoptosis signaling by Apo2L/TRAIL
- (2010) F Gonzalvez et al. ONCOGENE
- Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors
- (2009) H. A. Wakelee et al. ANNALS OF ONCOLOGY
- TRAIL-Induced Apoptosis
- (2009) Nadia Corazza et al. Annals of the New York Academy of Sciences
- Critical aspects of the Bayesian approach to phase I cancer trials
- (2008) Beat Neuenschwander et al. STATISTICS IN MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More